Eric Devroe - 18 May 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Operating Officer
Issuer ticker: ACRV
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2026, 16:29:31 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 20 May 2026.

Key facts

This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 16:29.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001950573 Primary reporting owner

Devroe Eric

Relationship: Chief Operating Officer
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Award

Transaction value
Shares: +72,981
Change %: +99%
Price: $0.000000^*
Shares after: 146,953
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.